Skip to main content
Erschienen in: Supportive Care in Cancer 2/2019

12.07.2018 | Original Article

Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants

verfasst von: Jennifer L. Moss, Jeanne Murphy, Virginia L. Filiaci, Lari B. Wenzel, Lori Minasian, Sarah M. Temkin

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Social determinants may influence health-related quality of life (HRQOL) among women with ovarian cancer, potentially creating disparities in clinical outcomes. We investigated the relationship between HRQOL and social determinants of health, including travel distance to access cancer care and health insurance type, among women participating in a randomized trial of primary adjuvant treatment for advanced ovarian cancer.

Methods

The Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaire captured HRQOL (physical well-being, functional well-being, ovarian-specific, and trial outcome index [TOI]) prior to chemotherapy (baseline), during the trial, and 84 weeks after initiation of chemotherapy for women with advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. We constructed bivariate and multivariable linear mixed effects models examining the associations of social determinants of health (individual-level and contextual factors) with HRQOL scores at 84 weeks, clustering participants (n = 993) within treatment centers, and Census regions and controlling for baseline HRQOL.

Results

Most individual-level (race, age, cancer stage, adverse events) and contextual (travel distance to treatment center, community socioeconomic status) factors were not statistically significantly associated with HRQOL. Compared to participants with private health insurance, other participants had lower mean HRQOL (physical well-being: public insurance, − 1.00 (standard error[SE] = 0.49) points, uninsured, − 1.93 (SE = 0.63) points; functional well-being: public, − 1.29 (SE = 0.59), uninsured, − 1.98 (SE = 0.76); ovarian cancer-specific: public, − 1.60 (SE = 0.59), uninsured, − 1.66 (SE = 0.75); TOI: public, − 3.81 (SE = 1.46), uninsured, − 5.51 (SE = 1.86); all p < .05).

Conclusions

Private health insurance was associated with improved HRQOL at the completion of treatment for advanced stage ovarian cancer. Implications of health insurance on HRQOL should be further investigated, particularly among women with ovarian cancer who receive standard of care treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384:1376–1388CrossRef Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384:1376–1388CrossRef
2.
Zurück zum Zitat Keim-Malpass J, Mihalko SL, Russell G, Case D, Miller B, Avis NE (2017) Problems experienced by ovarian cancer survivors during treatment. J Obstet Gynecol Neonatal Nurs 46:544–554CrossRef Keim-Malpass J, Mihalko SL, Russell G, Case D, Miller B, Avis NE (2017) Problems experienced by ovarian cancer survivors during treatment. J Obstet Gynecol Neonatal Nurs 46:544–554CrossRef
3.
Zurück zum Zitat Kornblith AB, Thaler HT, Wong G, Vlamis V, McCarthylepore J, Loseth DB et al (1995) Quality of life of women with ovarian cancer. Gynecol Oncol 59:231–242CrossRef Kornblith AB, Thaler HT, Wong G, Vlamis V, McCarthylepore J, Loseth DB et al (1995) Quality of life of women with ovarian cancer. Gynecol Oncol 59:231–242CrossRef
4.
Zurück zum Zitat Ahmed-Lecheheb D, Joly F (2016) Ovarian cancer survivors’ quality of life: a systematic review. J Cancer Surviv 10:789–801CrossRef Ahmed-Lecheheb D, Joly F (2016) Ovarian cancer survivors’ quality of life: a systematic review. J Cancer Surviv 10:789–801CrossRef
5.
Zurück zum Zitat Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, Sood AK (2017) Quality of life among long-term survivors of advanced stage ovarian cancer: a cross-sectional approach. Gynecol Oncol 146:101–108CrossRef Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, Sood AK (2017) Quality of life among long-term survivors of advanced stage ovarian cancer: a cross-sectional approach. Gynecol Oncol 146:101–108CrossRef
6.
Zurück zum Zitat Doll KM, Pinheiro LC, Reeve BB (2017) Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: a SEER-MHOS study. Gynecol Oncol 144:348–353CrossRef Doll KM, Pinheiro LC, Reeve BB (2017) Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: a SEER-MHOS study. Gynecol Oncol 144:348–353CrossRef
7.
Zurück zum Zitat Bandera EV, Lee VS, Rodriguez-Rodriguez L, Powell CB, Kushi LH (2016) Racial/ethnic disparities in ovarian cancer treatment and survival. Clin Cancer Res 22:5909–5914CrossRef Bandera EV, Lee VS, Rodriguez-Rodriguez L, Powell CB, Kushi LH (2016) Racial/ethnic disparities in ovarian cancer treatment and survival. Clin Cancer Res 22:5909–5914CrossRef
8.
Zurück zum Zitat Bristow RE, Chang J, Ziogas A, Anton-Culver H, Vieira VM (2014) Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol 134:60–67CrossRef Bristow RE, Chang J, Ziogas A, Anton-Culver H, Vieira VM (2014) Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol 134:60–67CrossRef
9.
Zurück zum Zitat Bristow RE, Powell MA, Al-Hammadi N, Chen L, Miller JP, Roland PY et al (2013) Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 105:823–832CrossRef Bristow RE, Powell MA, Al-Hammadi N, Chen L, Miller JP, Roland PY et al (2013) Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 105:823–832CrossRef
10.
Zurück zum Zitat Terplan M, Schluterman N, McNamara EJ, Tracy JK, Temkin SM (2012) Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol 125:19–24CrossRef Terplan M, Schluterman N, McNamara EJ, Tracy JK, Temkin SM (2012) Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol 125:19–24CrossRef
11.
Zurück zum Zitat Zeng C, Wen W, Morgans AK, Pao W, Shu X-O, Zheng W (2015) Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1990 to 2010. JAMA Oncol 1:88–96CrossRef Zeng C, Wen W, Morgans AK, Pao W, Shu X-O, Zheng W (2015) Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1990 to 2010. JAMA Oncol 1:88–96CrossRef
12.
Zurück zum Zitat Vieira VM, Villanueva C, Chang J, Ziogas A, Bristow RE (2017) Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California. Environ Res 156:388–393CrossRef Vieira VM, Villanueva C, Chang J, Ziogas A, Bristow RE (2017) Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California. Environ Res 156:388–393CrossRef
13.
Zurück zum Zitat Jones A, Haynes R, Sauerzapf V, Crawford S, Zhao H, Forman D (2008) Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer 44:992–999CrossRef Jones A, Haynes R, Sauerzapf V, Crawford S, Zhao H, Forman D (2008) Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer 44:992–999CrossRef
14.
Zurück zum Zitat Jones A, Haynes R, Sauerzapf V, Crawford S, Zhao H, Forman D (2008) Travel times to health care and survival from cancers in Northern England. Eur J Cancer 44:269–274CrossRef Jones A, Haynes R, Sauerzapf V, Crawford S, Zhao H, Forman D (2008) Travel times to health care and survival from cancers in Northern England. Eur J Cancer 44:269–274CrossRef
15.
Zurück zum Zitat Ambroggi M, Biasini C, Del Giovane C, Fornari F, Cavanna L (2015) Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist 20:1378–1385CrossRef Ambroggi M, Biasini C, Del Giovane C, Fornari F, Cavanna L (2015) Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist 20:1378–1385CrossRef
16.
Zurück zum Zitat Temkin SM, Fleming SA, Amrane S, Schluterman N, Terplan M (2015) Geographic disparities amongst patients with gynecologic malignancies at an urban NCI-designated cancer center. Gynecol Oncol 137:497–502CrossRef Temkin SM, Fleming SA, Amrane S, Schluterman N, Terplan M (2015) Geographic disparities amongst patients with gynecologic malignancies at an urban NCI-designated cancer center. Gynecol Oncol 137:497–502CrossRef
17.
Zurück zum Zitat Tanke MA, Ikkersheim DE (2012) A new approach to the tradeoff between quality and accessibility of health care. Health Policy 105:282–287CrossRef Tanke MA, Ikkersheim DE (2012) A new approach to the tradeoff between quality and accessibility of health care. Health Policy 105:282–287CrossRef
18.
Zurück zum Zitat Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX, Gynecologic Oncology Group (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483CrossRef Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX, Gynecologic Oncology Group (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483CrossRef
20.
21.
Zurück zum Zitat Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, Webster K, Cella D, Hu S, Gershenson DM (2001) Reliability and validity of the functional assessment of cancer therapy–ovarian. J Clin Oncol 19:1809–1817CrossRef Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, Webster K, Cella D, Hu S, Gershenson DM (2001) Reliability and validity of the functional assessment of cancer therapy–ovarian. J Clin Oncol 19:1809–1817CrossRef
22.
Zurück zum Zitat Phibbs CS, Luft HS (1995) Correlation of travel time on roads versus straight line distance. Med Care Res Rev 52:532–542CrossRef Phibbs CS, Luft HS (1995) Correlation of travel time on roads versus straight line distance. Med Care Res Rev 52:532–542CrossRef
23.
Zurück zum Zitat Mishkin G, Minasian LM, Kohn EC, Noone A-M, Temkin SM (2016) The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies. Gynecol Oncol 143:611–616CrossRef Mishkin G, Minasian LM, Kohn EC, Noone A-M, Temkin SM (2016) The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies. Gynecol Oncol 143:611–616CrossRef
24.
Zurück zum Zitat Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel L (2013) Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 128:573–578CrossRef Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel L (2013) Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 128:573–578CrossRef
25.
Zurück zum Zitat Luckett T, King M, Butow P, Friedlander M, Paris T (2010) Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change. Int J Gynecol Cancer 20:664–684CrossRef Luckett T, King M, Butow P, Friedlander M, Paris T (2010) Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change. Int J Gynecol Cancer 20:664–684CrossRef
26.
Zurück zum Zitat Krieger N, Chen JT, Waterman PD, Soobader M-J, Subramanian S, Carson R (2002) Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter? The public health disparities geocoding project. Am J Epidemiol 156:471–482CrossRef Krieger N, Chen JT, Waterman PD, Soobader M-J, Subramanian S, Carson R (2002) Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter? The public health disparities geocoding project. Am J Epidemiol 156:471–482CrossRef
27.
Zurück zum Zitat Von Gruenigen VE, Huang HQ, Gil KM, Frasure HE, Armstrong DK, Wenzel LB (2012) The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol 124:379–382CrossRef Von Gruenigen VE, Huang HQ, Gil KM, Frasure HE, Armstrong DK, Wenzel LB (2012) The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol 124:379–382CrossRef
28.
Zurück zum Zitat Nayfield S, Ganz P, Moinpour C, Cella D, Hailey B (1992) Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Qual Life Res 1:203–210CrossRef Nayfield S, Ganz P, Moinpour C, Cella D, Hailey B (1992) Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Qual Life Res 1:203–210CrossRef
29.
Zurück zum Zitat Phippen N, Secord A, Wolf S, Samsa G, Davidson B, Abernethy A et al (2017) Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: an ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. Gynecol Oncol 147:98–103CrossRef Phippen N, Secord A, Wolf S, Samsa G, Davidson B, Abernethy A et al (2017) Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: an ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. Gynecol Oncol 147:98–103CrossRef
30.
Zurück zum Zitat Baicker K, Chandra A (2017) Evidence-based health policy. N Engl J Med 377:2413–2415CrossRef Baicker K, Chandra A (2017) Evidence-based health policy. N Engl J Med 377:2413–2415CrossRef
31.
Zurück zum Zitat Hoffman C, Paradise J (2008) Health insurance and access to health care in the United States. Ann N Y Acad Sci 1136:149–160CrossRef Hoffman C, Paradise J (2008) Health insurance and access to health care in the United States. Ann N Y Acad Sci 1136:149–160CrossRef
32.
Zurück zum Zitat Walker GV, Grant SR, Guadagnolo BA, Hoffman KE, Smith BD, Koshy M, Allen PK, Mahmood U (2014) Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol 32:3118–3125CrossRef Walker GV, Grant SR, Guadagnolo BA, Hoffman KE, Smith BD, Koshy M, Allen PK, Mahmood U (2014) Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol 32:3118–3125CrossRef
33.
Zurück zum Zitat Eom CS, Shin DW, Kim SY, Yang HK, Jo HS, Kweon SS, Kang YS, Kim JH, Cho BL, Park JH (2013) Impact of perceived social support on the mental health and health-related quality of life in cancer patients: results from a nationwide, multicenter survey in South Korea. Psycho-Oncology 22:1283–1290CrossRef Eom CS, Shin DW, Kim SY, Yang HK, Jo HS, Kweon SS, Kang YS, Kim JH, Cho BL, Park JH (2013) Impact of perceived social support on the mental health and health-related quality of life in cancer patients: results from a nationwide, multicenter survey in South Korea. Psycho-Oncology 22:1283–1290CrossRef
34.
Zurück zum Zitat Niu X, Roche LM, Pawlish KS, Henry KA (2013) Cancer survival disparities by health insurance status. Cancer Med 2:403–411CrossRef Niu X, Roche LM, Pawlish KS, Henry KA (2013) Cancer survival disparities by health insurance status. Cancer Med 2:403–411CrossRef
35.
Zurück zum Zitat Warren JL, Butler EN, Stevens J, Lathan CS, Noone A-M, Ward KC, Harlan LC (2015) Receipt of chemotherapy among Medicare patients with Cancer by type of supplemental insurance. J Clin Oncol 33:312–318CrossRef Warren JL, Butler EN, Stevens J, Lathan CS, Noone A-M, Ward KC, Harlan LC (2015) Receipt of chemotherapy among Medicare patients with Cancer by type of supplemental insurance. J Clin Oncol 33:312–318CrossRef
Metadaten
Titel
Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants
verfasst von
Jennifer L. Moss
Jeanne Murphy
Virginia L. Filiaci
Lari B. Wenzel
Lori Minasian
Sarah M. Temkin
Publikationsdatum
12.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4340-9

Weitere Artikel der Ausgabe 2/2019

Supportive Care in Cancer 2/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.